Lancet infect dis: The preventive effectofs of early intervention in Balosawe on flu complications

Barosavemarboxil (hereinafter referred to as Balosavir) is a selective inhibitor of influenza cap-dependent nucleic acid endoenzymes and has been approved in the United States and Japan in 2018 to treat simple influenza in healthy people over the age of 12The purpose of this study was to assess the efficacy of Balosawe in outpatient sandpatients at high risk of flu-related complicationsthis is a double-blind placebo-and-oseltamivir-controlled trial that recruited outpatients with influenza-like diseases 12 years and older with clinicallydiagnosisin 551 locations in several countries with clinically diagnosed(symptoms persist ingons of 48h), and at least one risk factor for influenza-related complications (e.g., 65 years of age)The main endpoint is the time when flu symptoms improve (TTIIS) in the intended treatment population11 January 2017 -March 30, 2018, a total of 2,184 patients were recruited, randomly assigned to the Balosawe group (730), the placebo group (729) or the oseltamivir group (725)The corrected intentional treatment group consisted of 1,163 people: 388 in the Balosave group, 386 in the placebo group, and 389 in the oseltamivir groupof 1163 patients, 557 (48%) were influenza A(H3N2), 484 (42%) were influenza B, 80 (7%) were influenza A(H1N1), 14 were mixed, and 28 were infected with influenza AThe median TTIIS in the Oseltamivir group is 81.0h (95% CI 69.4 to 91.5), a significant gap from the 7.7h (-7.9 to 22.7) in the Babashawe groupThe incidence of adverse reactions was 25% in the Barosave group, 30% in the placebo group and 28% in the oseltamivir groupThe Balosave group reported 5 cases of severe adverse reactions, 9 cases in the placebo group and 8 cases in the oseltamivir group, 1 case of hypertension and 1 case of nausea in the placebo group, and 2 cases of elevated transaminase in the oseltamivir group were found to be associated with treatmentPolymerase acid proteins carrying Ile38Thr, Ile38Met or Ile38Asn mutations were less sensitive to Balosawe, with a 5% (15 cases) incidence in the Balosawe groupsingle dose of Balosavir has a better effect than placebo in improving flu symptoms in high-risk outpatients, comparable to oseltamivir Barosave's safety is comparable to that of placebos The results of this study support early treatment of patients at high risk of influenza complications to accelerate clinical recovery and reduce complications